Short and long-term acceptability and efficacy of extended-release cornstarch in the hepatic glycogen storage diseases: results from the Glyde study.
Weinstein DAJackson RjBrennan EaWilliams MDavison Jede Boer FDerks TgjEllerton CFaragher BGribben JLabrune PMcKittrick KmMurphy ERoss KmSteuerwald UVoillot CWoodward AjmMundy HrPublished in: Orphanet journal of rare diseases (2024)
The Glyde study is the first multi-centre international trial demonstrating the efficacy and tolerance of Glycosade in a large cohort of hepatic GSD patients across a diverse international population. The ability to use fewer doses of therapy per day and avoidance of overnight therapy may improve compliance, safety, and quality of life without sacrificing metabolic control.